Wild-Type and Met-65 → Leu Variants of Human Cystatin A Are Functionally and Structurally Identical
The solution structure of an N-terminally truncated and mutant form (M65L2-98) of the human cysteine protease inhibitor cystatin A has been reported that reveals extensive structural differences when compared to the previously published structure of full-length wild-type (WT) cystatin A. On the basi...
Saved in:
Published in | Biochemistry (Easton) Vol. 39; no. 51; pp. 15783 - 15790 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
26.12.2000
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The solution structure of an N-terminally truncated and mutant form (M65L2-98) of the human cysteine protease inhibitor cystatin A has been reported that reveals extensive structural differences when compared to the previously published structure of full-length wild-type (WT) cystatin A. On the basis of the M65L2-98 structure, a model of the inhibitory mechanism of cystatin A was proposed wherein specific interactions between the N- and C-terminal regions of cystatin A are invoked as critical determinants of protease binding. To test this model and to account for the reported differences between the two structures, we undertook additional structural and mechanistic analyses of WT and mutant forms of human cystatin A. These show that modification at the C-terminus of cystatin A by the addition of nine amino acids has no effect upon the affinity of papain inhibition (K D = 0.18 ± 0.02 pM) and the consequences of such modification are not propagated to other parts of the structure. These findings indicate that perturbation of the C-terminus can be achieved without any measurable effect on the N-terminus or the proteinase binding loops. In addition, introduction of the methionine-65 → leucine substitution into cystatin A that retains the N-terminal methionine (M65L1-98) has no significant effect upon papain binding (K D = 0.34 ± 0.02 pM). Analyses of the structures of WT and M65L1-98 using 1H NMR chemical shifts and residual dipolar couplings in a partially aligning medium do not reveal any evidence of significant differences between the two inhibitors. Many of the differences between the published structures correspond to major violations by M65L2-98 of the WT constraints list, notably in relation to the position of the N-terminal region of the inhibitor, one of three structural motifs indicated by crystallographic studies to be involved in protease binding by cystatins. In the WT structure, and consistent with the crystallographic data, this region is positioned adjacent to another inhibitory motif (the first binding loop), whereas in M65L2-98 there is no proximity of these two motifs. As the NMR data for both WT9C and M65L1-98 are wholly consistent with the published structure of WT cystatin A and incompatible with that of M65L2-98, we conclude that the former represents the most reliable structural model of this protease inhibitor. |
---|---|
AbstractList | The solution structure of an N-terminally truncated and mutant form (M65L2-98) of the human cysteine protease inhibitor cystatin A has been reported that reveals extensive structural differences when compared to the previously published structure of full-length wild-type (WT) cystatin A. On the basis of the M65L2-98 structure, a model of the inhibitory mechanism of cystatin A was proposed wherein specific interactions between the N- and C-terminal regions of cystatin A are invoked as critical determinants of protease binding. To test this model and to account for the reported differences between the two structures, we undertook additional structural and mechanistic analyses of WT and mutant forms of human cystatin A. These show that modification at the C-terminus of cystatin A by the addition of nine amino acids has no effect upon the affinity of papain inhibition (K D = 0.18 ± 0.02 pM) and the consequences of such modification are not propagated to other parts of the structure. These findings indicate that perturbation of the C-terminus can be achieved without any measurable effect on the N-terminus or the proteinase binding loops. In addition, introduction of the methionine-65 → leucine substitution into cystatin A that retains the N-terminal methionine (M65L1-98) has no significant effect upon papain binding (K D = 0.34 ± 0.02 pM). Analyses of the structures of WT and M65L1-98 using 1H NMR chemical shifts and residual dipolar couplings in a partially aligning medium do not reveal any evidence of significant differences between the two inhibitors. Many of the differences between the published structures correspond to major violations by M65L2-98 of the WT constraints list, notably in relation to the position of the N-terminal region of the inhibitor, one of three structural motifs indicated by crystallographic studies to be involved in protease binding by cystatins. In the WT structure, and consistent with the crystallographic data, this region is positioned adjacent to another inhibitory motif (the first binding loop), whereas in M65L2-98 there is no proximity of these two motifs. As the NMR data for both WT9C and M65L1-98 are wholly consistent with the published structure of WT cystatin A and incompatible with that of M65L2-98, we conclude that the former represents the most reliable structural model of this protease inhibitor. The solution structure of an N-terminally truncated and mutant form (M65L(2-98)) of the human cysteine protease inhibitor cystatin A has been reported that reveals extensive structural differences when compared to the previously published structure of full-length wild-type (WT) cystatin A. On the basis of the M65L(2-98) structure, a model of the inhibitory mechanism of cystatin A was proposed wherein specific interactions between the N- and C-terminal regions of cystatin A are invoked as critical determinants of protease binding. To test this model and to account for the reported differences between the two structures, we undertook additional structural and mechanistic analyses of WT and mutant forms of human cystatin A. These show that modification at the C-terminus of cystatin A by the addition of nine amino acids has no effect upon the affinity of papain inhibition (K(D) = 0.18+/-0.02 pM) and the consequences of such modification are not propagated to other parts of the structure. These findings indicate that perturbation of the C-terminus can be achieved without any measurable effect on the N-terminus or the proteinase binding loops. In addition, introduction of the methionine-65 --> leucine substitution into cystatin A that retains the N-terminal methionine (M65L(1-98)) has no significant effect upon papain binding (K(D) = 0.34+/-0.02 pM). Analyses of the structures of WT and M65L(1-98) using (1)H NMR chemical shifts and residual dipolar couplings in a partially aligning medium do not reveal any evidence of significant differences between the two inhibitors. Many of the differences between the published structures correspond to major violations by M65L(2-98) of the WT constraints list, notably in relation to the position of the N-terminal region of the inhibitor, one of three structural motifs indicated by crystallographic studies to be involved in protease binding by cystatins. In the WT structure, and consistent with the crystallographic data, this region is positioned adjacent to another inhibitory motif (the first binding loop), whereas in M65L(2-98) there is no proximity of these two motifs. As the NMR data for both WT9C and M65L(1-98) are wholly consistent with the published structure of WT cystatin A and incompatible with that of M65L(2-98), we conclude that the former represents the most reliable structural model of this protease inhibitor. |
Author | Murray, Ewan H Martin, John R Craven, C. Jeremy Baxter, Nicola J Hill, Nicola J Waltho, Jonathan P Ylinenjärvi, Karin Björk, Ingemar Murray, Iain A |
Author_xml | – sequence: 1 givenname: C. Jeremy surname: Craven fullname: Craven, C. Jeremy – sequence: 2 givenname: Nicola J surname: Baxter fullname: Baxter, Nicola J – sequence: 3 givenname: Ewan H surname: Murray fullname: Murray, Ewan H – sequence: 4 givenname: Nicola J surname: Hill fullname: Hill, Nicola J – sequence: 5 givenname: John R surname: Martin fullname: Martin, John R – sequence: 6 givenname: Karin surname: Ylinenjärvi fullname: Ylinenjärvi, Karin – sequence: 7 givenname: Ingemar surname: Björk fullname: Björk, Ingemar – sequence: 8 givenname: Jonathan P surname: Waltho fullname: Waltho, Jonathan P – sequence: 9 givenname: Iain A surname: Murray fullname: Murray, Iain A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11123903$$D View this record in MEDLINE/PubMed |
BookMark | eNptkEtOwzAQhi1URMtjwQWQNyxYBMZ27MTLqlBAKi9RYGk5sSulpE5lOxK9AAfgiJyEQFHZsBrNzKd_NN8u6rnGWYQOCZwSoOSsqABIBkJuoQHhFJJUSt5DAwAQCZUC-mg3hHnXppClO6hPCKFMAhsg-1LVJpmulhZrZ_CNjYng-PP9A09si5-1r7SLATczfNUutMOjVYg6Vg4P8dBbPG5dGavG6bpe_QQ8Rt-WsfU_g2tjXaxKXe-j7Zmugz34rXvoaXwxHV0lk7vL69FwkmiWypjIIjccdCm1sbzsHmKc24ISKjinRjAjZS4LmXPKrSDSgDA5pHlqZcEELWdsD52sc0vfhODtTC19tdB-pQiob1Vqo6pjj9bssi0W1vyRv246IFkDVYj2bbPX_lWJjGVcTe8fFZzfZsDSB_UdeLzmdRnUvGl9ZyX8c_gLYAJ_FA |
CitedBy_id | crossref_primary_10_1016_S0959_440X_00_00245_1 crossref_primary_10_1046_j_1432_1033_2002_03273_x |
Cites_doi | 10.1016/0014-5793(91)80804-C 10.1006/jmbi.1999.3045 10.1021/ja982671r 10.1042/bj2990219 10.1111/j.1432-1033.1994.1181b.x 10.1006/jmrb.1993.1008 10.1042/bj2810049 10.1074/jbc.271.3.1314 10.1006/jmbi.1997.1150 10.1111/j.1528-1157.1999.tb00903.x 10.1111/j.1365-2133.1983.tb03996.x 10.1002/j.1460-2075.1990.tb08321.x 10.1107/S0021889891004399 10.1006/jmbi.1994.0088 10.1042/bj3060513 10.1126/science.278.5340.1111 10.1006/jmre.1998.1361 10.1046/j.1432-1327.1999.00312.x |
ContentType | Journal Article |
Copyright | Copyright © 2000 American Chemical Society |
Copyright_xml | – notice: Copyright © 2000 American Chemical Society |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1021/bi0017069 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1520-4995 |
EndPage | 15790 |
ExternalDocumentID | 10_1021_bi0017069 11123903 ark_67375_TPS_0DN7034Q_9 c978714838 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | - .K2 02 08R 186 23N 3O- 4.4 53G 55 55A 5GY 5RE 5VS 7~N 85S AABXI AAYJJ ABFLS ABMVS ABOCM ABPTK ABUCX ABUFD ACGFS ACJ ACNCT ACS ADKFC AEESW AENEX AETEA AFEFF AFFDN AFFNX AFMIJ AIDAL AJYGW ALMA_UNASSIGNED_HOLDINGS ANTXH AQSVZ BAANH CS3 D0L DU5 DZ EBS ED ED~ EJD F5P G8K GJ GNL IH9 IHE JG JG~ K2 K78 KM L7B LG6 MVM NHB OHT P2P ROL TN5 UI2 UNC UQL VF5 VG9 VQA W1F WH7 X X7M YZZ ZA5 ZE2 ZGI ZXP --- -DZ -~X .55 .GJ 6TJ ABFRP ABJNI ABQRX ADHLV AEQTP AGHSJ AGXLV AHGAQ BSCLL GGK XOL XSW YYP ZCA ~02 ~KM CGR CUPRZ CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-a349t-9b8d50ac9ade5c706355eb2126552d63d9989b98525e619d06d80484e9b362cf3 |
IEDL.DBID | ACS |
ISSN | 0006-2960 |
IngestDate | Thu Sep 26 18:02:14 EDT 2024 Sat Sep 28 08:40:15 EDT 2024 Wed Jan 17 04:50:40 EST 2024 Thu Aug 27 13:43:02 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 51 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a349t-9b8d50ac9ade5c706355eb2126552d63d9989b98525e619d06d80484e9b362cf3 |
Notes | ark:/67375/TPS-0DN7034Q-9 We thank the Lister Institute for Preventive Medicine, the Wellcome Trust, the Biotechnology and Biological Sciences Research Council, the British Heart Foundation, and the Swedish Medical Research Council for financial support. istex:5AA42443EFDC38A68447C2ED154A356F44CD8EB2 |
PMID | 11123903 |
PageCount | 8 |
ParticipantIDs | crossref_primary_10_1021_bi0017069 pubmed_primary_11123903 istex_primary_ark_67375_TPS_0DN7034Q_9 acs_journals_10_1021_bi0017069 |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ANTXH ACS AEESW AFEFF .K2 ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 2000-12-26 |
PublicationDateYYYYMMDD | 2000-12-26 |
PublicationDate_xml | – month: 12 year: 2000 text: 2000-12-26 day: 26 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Biochemistry (Easton) |
PublicationTitleAlternate | Biochemistry |
PublicationYear | 2000 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | Björk I. (bi0017069b00016/bi0017069b00016_1) 1994; 299 Prosser R. S. (bi0017069b00026/bi0017069b00026_1) 1998; 120 Rinne A. (bi0017069b00003/bi0017069b00003_1) 1979 Turk V. (bi0017069b00001/bi0017069b00001_1) 1991; 285 Barrett A. J. (bi0017069b00002/bi0017069b00002_1) 1986 Ottiger M. (bi0017069b00027/bi0017069b00027_1) 1998; 131 Tate S. (bi0017069b00014/bi0017069b00014_1) 1995 Lindahl P. (bi0017069b00028/bi0017069b00028_1) 1988 Lalioti M. D. (bi0017069b00010/bi0017069b00010_1) 1997; 60 Martin J. R. (bi0017069b00013/bi0017069b00013_1) 1995; 246 Shibuya K. (bi0017069b00018/bi0017069b00018_1) 1995 Björk I. (bi0017069b00017/bi0017069b00017_1) 1995; 306 Pol E. (bi0017069b00021/bi0017069b00021_1) 1999 Stubbs M. T. (bi0017069b00012/bi0017069b00012_1) 1990; 9 Pol E. (bi0017069b00022/bi0017069b00022_1) 1995; 311 Williamson M. P. (bi0017069b00024/bi0017069b00024_1) 1993; 101 Lah T. T. (bi0017069b00005/bi0017069b00005_1) 1990 Tjandra N. (bi0017069b00025/bi0017069b00025_1) 1997; 278 Ekiel I. (bi0017069b00032/bi0017069b00032_1) 1997; 271 Pennacchio L. A. (bi0017069b00008/bi0017069b00008_1) 1996 Kraulis P. J. (bi0017069b00033/bi0017069b00033_1) 1991; 24 Abbreviations WT (bi0017069n00001/bi0017069n00001_1) Jerala R (bi0017069b00030/bi0017069b00030_1) 1999; 291 Lindahl P. (bi0017069b00029/bi0017069b00029_1) 1992; 281 Rinne A. (bi0017069b00004/bi0017069b00004_1) 1980; 22 Estrada S. (bi0017069b00011/bi0017069b00011_1) 1998 Kaji H. (bi0017069b00015/bi0017069b00015_1) 1990 Hopsu-Havu V. K. (bi0017069b00006/bi0017069b00006_1) 1983; 109 Lehejoski A. E. (bi0017069b00009/bi0017069b00009_1) 1999; 40 Estrada S. (bi0017069b00019/bi0017069b00019_1) 1999 Ylinenjärvi K. (bi0017069b00020/bi0017069b00020_1) 1999; 261 Martin J. R. (bi0017069b00023/bi0017069b00023_1) 1994; 225 Ekiel I. (bi0017069b00031/bi0017069b00031_1) 1996; 271 Hopsu-Havu V. K. (bi0017069b00007/bi0017069b00007_1) 1983; 5 |
References_xml | – volume-title: Science 271, 1731−1734 year: 1996 ident: bi0017069b00008/bi0017069b00008_1 contributor: fullname: Pennacchio L. A. – volume: 285 year: 1991 ident: bi0017069b00001/bi0017069b00001_1 publication-title: FEBS Lett. doi: 10.1016/0014-5793(91)80804-C contributor: fullname: Turk V. – volume: 291 year: 1999 ident: bi0017069b00030/bi0017069b00030_1 publication-title: J. Mol. Biol. doi: 10.1006/jmbi.1999.3045 contributor: fullname: Jerala R – volume: 120 year: 1998 ident: bi0017069b00026/bi0017069b00026_1 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja982671r contributor: fullname: Prosser R. S. – volume: 299 year: 1994 ident: bi0017069b00016/bi0017069b00016_1 publication-title: Biochem. J. doi: 10.1042/bj2990219 contributor: fullname: Björk I. – volume: 225 year: 1994 ident: bi0017069b00023/bi0017069b00023_1 publication-title: . Eur. J. Biochem. doi: 10.1111/j.1432-1033.1994.1181b.x contributor: fullname: Martin J. R. – volume-title: Biochemistry 38, 10519−10526 year: 1999 ident: bi0017069b00021/bi0017069b00021_1 contributor: fullname: Pol E. – volume-title: Biochemistry 27, 5074−5082 year: 1988 ident: bi0017069b00028/bi0017069b00028_1 contributor: fullname: Lindahl P. – volume: 101 start-page: 71 year: 1993 ident: bi0017069b00024/bi0017069b00024_1 publication-title: J. Magn. Reson. B doi: 10.1006/jmrb.1993.1008 contributor: fullname: Williamson M. P. – volume: 281 start-page: 55 year: 1992 ident: bi0017069b00029/bi0017069b00029_1 publication-title: Biochem. J. doi: 10.1042/bj2810049 contributor: fullname: Lindahl P. – volume-title: Biochemistry 34, 12185−12192 year: 1995 ident: bi0017069b00018/bi0017069b00018_1 contributor: fullname: Shibuya K. – volume-title: Biochemistry 34, 14637−14648 year: 1995 ident: bi0017069b00014/bi0017069b00014_1 contributor: fullname: Tate S. – volume: 271 year: 1996 ident: bi0017069b00031/bi0017069b00031_1 publication-title: J. Biol. Chem. doi: 10.1074/jbc.271.3.1314 contributor: fullname: Ekiel I. – volume-title: Biochemistry 38, 7339−7345 year: 1999 ident: bi0017069b00019/bi0017069b00019_1 contributor: fullname: Estrada S. – volume: 271 year: 1997 ident: bi0017069b00032/bi0017069b00032_1 publication-title: J. Mol. Biol. doi: 10.1006/jmbi.1997.1150 contributor: fullname: Ekiel I. – volume-title: Biol. Chem. Hoppe-Seyler 371, 199−203 year: 1990 ident: bi0017069b00005/bi0017069b00005_1 contributor: fullname: Lah T. T. – volume: 40 start-page: 28 year: 1999 ident: bi0017069b00009/bi0017069b00009_1 publication-title: Epilepsia doi: 10.1111/j.1528-1157.1999.tb00903.x contributor: fullname: Lehejoski A. E. – volume: 109 start-page: 85 year: 1983 ident: bi0017069b00006/bi0017069b00006_1 publication-title: Br. J. Dermatol. doi: 10.1111/j.1365-2133.1983.tb03996.x contributor: fullname: Hopsu-Havu V. K. – volume: 9 year: 1990 ident: bi0017069b00012/bi0017069b00012_1 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1990.tb08321.x contributor: fullname: Stubbs M. T. – volume: 311 year: 1995 ident: bi0017069b00022/bi0017069b00022_1 publication-title: Biochem. J. contributor: fullname: Pol E. – volume: 24 year: 1991 ident: bi0017069b00033/bi0017069b00033_1 publication-title: J. Appl. Crystallogr. doi: 10.1107/S0021889891004399 contributor: fullname: Kraulis P. J. – volume: 246 year: 1995 ident: bi0017069b00013/bi0017069b00013_1 publication-title: J. Mol. Biol. doi: 10.1006/jmbi.1994.0088 contributor: fullname: Martin J. R. – volume-title: wild-type cystatin A ident: bi0017069n00001/bi0017069n00001_1 contributor: fullname: Abbreviations WT – volume: 60 year: 1997 ident: bi0017069b00010/bi0017069b00010_1 publication-title: Am. J. Hum. Genet. contributor: fullname: Lalioti M. D. – volume: 306 year: 1995 ident: bi0017069b00017/bi0017069b00017_1 publication-title: Biochem. J. doi: 10.1042/bj3060513 contributor: fullname: Björk I. – start-page: 569 volume-title: A. J. year: 1986 ident: bi0017069b00002/bi0017069b00002_1 contributor: fullname: Barrett A. J. – volume-title: Biochemistry 37, 7551−7560 year: 1998 ident: bi0017069b00011/bi0017069b00011_1 contributor: fullname: Estrada S. – volume: 278 start-page: 1697 year: 1997 ident: bi0017069b00025/bi0017069b00025_1 publication-title: Science doi: 10.1126/science.278.5340.1111 contributor: fullname: Tjandra N. – volume: 5 start-page: 4 year: 1983 ident: bi0017069b00007/bi0017069b00007_1 publication-title: Eur. Rev. Med. Pharm. Sci. contributor: fullname: Hopsu-Havu V. K. – volume: 131 year: 1998 ident: bi0017069b00027/bi0017069b00027_1 publication-title: J. Magn. Reson. doi: 10.1006/jmre.1998.1361 contributor: fullname: Ottiger M. – volume-title: Suppl., 145−150. year: 1990 ident: bi0017069b00015/bi0017069b00015_1 contributor: fullname: Kaji H. – volume: 261 year: 1999 ident: bi0017069b00020/bi0017069b00020_1 publication-title: Eur. J. Biochem. doi: 10.1046/j.1432-1327.1999.00312.x contributor: fullname: Ylinenjärvi K. – year: 1979 ident: bi0017069b00003/bi0017069b00003_1 publication-title: Acta Univ. Oulu. D41, Anat. Pathol. Microbiol. 4. contributor: fullname: Rinne A. – volume: 22 year: 1980 ident: bi0017069b00004/bi0017069b00004_1 publication-title: Acta Histochem., Suppl. contributor: fullname: Rinne A. |
SSID | ssj0004074 |
Score | 1.6847951 |
Snippet | The solution structure of an N-terminally truncated and mutant form (M65L2-98) of the human cysteine protease inhibitor cystatin A has been reported that... The solution structure of an N-terminally truncated and mutant form (M65L(2-98)) of the human cysteine protease inhibitor cystatin A has been reported that... |
SourceID | crossref pubmed istex acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 15783 |
SubjectTerms | Amino Acid Substitution - genetics Animals Chickens Cystatins - antagonists & inhibitors Cystatins - chemistry Cystatins - genetics Cystatins - physiology Genetic Variation Humans Hydrogen-Ion Concentration Kinetics Leucine - genetics Methionine - genetics Mutagenesis, Insertional Mutagenesis, Site-Directed Nuclear Magnetic Resonance, Biomolecular Papain - chemistry Peptide Fragments - chemistry Peptide Fragments - genetics Polymerase Chain Reaction Sequence Deletion Sequence Homology, Amino Acid Structure-Activity Relationship Titrimetry |
Title | Wild-Type and Met-65 → Leu Variants of Human Cystatin A Are Functionally and Structurally Identical |
URI | http://dx.doi.org/10.1021/bi0017069 https://api.istex.fr/ark:/67375/TPS-0DN7034Q-9/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/11123903 |
Volume | 39 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3JTsMwEB2xHODCVnaoLEDcXFLHDvGxKlQVAgRqQb1FduxIFRAQFInyAXwAn8iXMHZa9uUaOY7jsT3v2TPPAFsMWVUqMk7RFQjKw0xRlQpOEdoypeKQK38XwdFx1DzjBx3RGYHNX07wWXVHdwuNFzkK48xFDjr8U2-9Jz8GA6llpMYM8fhQPujjq871pHefXM-468WHL2DSO5XGNOwNU3OKWJKLyn1PV9LH70qNf7V3BqYGoJLUilEwCyM2n4NSLUdCfdUn28SHefr98zmYqA-veCuBxTXBUEdFicoNObI9Ggny8vRMDu09OUca7aJkyHVG_F4_qfdd_lE3JzX8liUN9InFVuJl31fQ8mK0TsgDHxQpwDgE5uGssd-uN-ng3gWqQi57VOrYiEClUhkrUvwVxCRIwKssEoKZKDRI0aSWsWDCIv8yQWRiXAi4lRrdYZqFCzCWX-d2CchupBHQ2UBbl4AbGy2M5TJWYWosi-J4GcpomGQwb-4SfyTOqslbJy7DxtBmyU2hv_FToW1vzbcS6vbCBaztiqR90kqCvWNc1_hpggUXC3O_14XNC2UQrvzXkFWY9Fn4VUZZtAZj2KF2HfFIT5f9eHwFCkjUiQ |
link.rule.ids | 315,786,790,2782,27109,27957,27958,57093,57143 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bT8IwFG68POiLN7zgtTGGt-ro2rE-EpSgAtGAxrelXUtC0GEEEvEH-AP8if4ST7shakz0dem6s9Ou5_u6c74idESBVcW8wwiEAk6Y35FExpwRgLZUytBn0p1F0GgGtRt2ccfvMpkcWwsDRgygp4H7iT9VFyieqG4q9SJm0TwvAQ-3MKjSmtZAepniMjBkCrB8oiL09VYbgeLBtwg0b535_ANTuthSXU4PKXJWuZSS3vFoqI7jlx-Cjf8zewUtZRATl9M5sYpmTLKGcuUE6PXDGBewS_p0u-lraKEyOfAthwysEJpYYoplonHDDEnA8fvrG66bEb4FUm1zZnC_g93OP66MbTVSN8FleJbBVYiQ6cbi_dh10HLStFbWAy6kBcEwIdbRTfWsXamR7BQGIn0mhkSoUHNPxkJqw2N4FUAoQMeLNOCc6sDXQNiEEiGn3AAb016gQ1gWmBEKgmPc8TfQXNJPzBbCpUABvDOeMrYcN9SKa8NEKP1YGxqEYR7tgw-j7CsaRO4HOS1Gn07Mo8PJ0EWPqRrHb40KblA_W8innk1fK_GofdWKvNMmrHLsOoKGm-moT_sC83zh-dt_GXKAFmrtRj2qnzcvd9Ciq88vUkKDXTQHzjV7gFSGat9N0Q-qEdz0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3JTsMwEB2xSMCFfd8shLgZUscO8bEqVKwFVEDcIjt2JAQERItE-QA-gE_kSxg7aVmEBNfIcSbjZd6zZwFYZ8iqUpFxiqZAUB5miqpUcIrQlikVh1z5WgTHjWjvgh9ciauSKLpYGBSihT21_CW-W9UPJiszDFS29HWR7kX2w6BwhbsdFKo1P-MggzLrMrJkhtC8m0no66vOCqWtb1Zo0Cn0-Qeu9PalPgYnPcm8W8nN5lNbb6YvP5I2_l_0cRgtoSapFnNjAvpsPglT1Rxp9l2HbBDv_OlP1SdhuNYt_DYFFncKQx1BJSo35Ni2aSTI--sbObJP5BLJtfOdIfcZ8TcApNZxUUnXOanityypo6UsDhhvO76Dpk9R69J74IMiMBgnxjRc1HfPa3u0rMZAVchlm0odGxGoVCpjRYq_gkgFaXmFRUIwE4UGiZvUMhZMWGRlJohMjNsDt1KjkUyzcAYG8vvczgHZjjTCPBto68JyY6OFsVzGKkyNZVEcz8MK6jEpV1Mr8RflrJL0lDgPa93hSx6KrBy_NdrwA9troR5vnBvbtkjOT5tJsNPA3Y6fJdhwthj5z75QvFAG4cJfgqzC0OlOPTnabxwuwogP068wyqIlGEDd2mUELG294mfpBwIE324 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Wild-Type+and+Met-65+%E2%86%92+Leu+Variants+of+Human+Cystatin+A+Are+Functionally+and+Structurally+Identical&rft.jtitle=Biochemistry+%28Easton%29&rft.au=Craven%2C+C.+Jeremy&rft.au=Baxter%2C+Nicola+J&rft.au=Murray%2C+Ewan+H&rft.au=Hill%2C+Nicola+J&rft.date=2000-12-26&rft.pub=American+Chemical+Society&rft.issn=0006-2960&rft.eissn=1520-4995&rft.volume=39&rft.issue=51&rft.spage=15783&rft.epage=15790&rft_id=info:doi/10.1021%2Fbi0017069&rft.externalDocID=c978714838 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2960&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2960&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2960&client=summon |